• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem, Inc. - Common Stock (NQ:VSTM)

    7.285 -0.055 (-0.75%)
    Streaming Delayed Price Updated: 11:03 AM EDT, Sep 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 218,604
    Open 7.350
    Bid (Size) 7.280 (1,000)
    Ask (Size) 7.290 (300)
    Prev. Close 7.340
    Today's Range 7.240 - 7.410
    52wk Range 3.430 - 10.82
    Shares Outstanding 77,740,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Participate in Upcoming September Investor Conferences
    From Verastem Oncology
    Via Business Wire

    Performance

    YTD
    +0.8%
    +0.8%
    1 Month
    +1.5%
    +1.5%
    3 Month
    +81.7%
    +81.7%
    6 Month
    +28.5%
    +28.5%
    1 Year
    -25.8%
    -25.8%

    More News

    Read More
    News headline image
    Verastem (VSTM) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
    Via Chartmill
    News headline image
    Verastem Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    News headline image
    VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Present at Jefferies Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Present at Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Verastem (VSTM) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
    From Verastem Oncology
    Via Business Wire

    Frequently Asked Questions

    Is Verastem, Inc. - Common Stock publicly traded?
    Yes, Verastem, Inc. - Common Stock is publicly traded.
    What exchange does Verastem, Inc. - Common Stock trade on?
    Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verastem, Inc. - Common Stock?
    The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
    What is the current price of Verastem, Inc. - Common Stock?
    The current price of Verastem, Inc. - Common Stock is 7.285
    When was Verastem, Inc. - Common Stock last traded?
    The last trade of Verastem, Inc. - Common Stock was at 09/16/26 11:03 AM ET
    What is the market capitalization of Verastem, Inc. - Common Stock?
    The market capitalization of Verastem, Inc. - Common Stock is 566.34M
    How many shares of Verastem, Inc. - Common Stock are outstanding?
    Verastem, Inc. - Common Stock has 566M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.